AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31733760 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in exercise behavior)
Number of subjects: 44
Study 28980368 — intervention group
Group type: EXPERIMENTAL
Intervention: Target dose enalapril (20 mg/day)
Number of subjects: 2569
Study 28980368 — intervention group
Group type: EXPERIMENTAL
Intervention: Below-target dose enalapril (5-10 mg/day)
Number of subjects: 2569
Study 28980368 — intervention group
Group type: COMPARATOR
Intervention: Target dose placebo (20 mg/day)
Number of subjects: 2569
Study 28980368 — intervention group
Group type: COMPARATOR
Intervention: Below-target dose placebo (5-10 mg/day)
Number of subjects: 2569
Study 28980368 — intervention group
Group type: EXPERIMENTAL
Intervention: Target dose enalapril vs. below-target dose enalapril
Number of subjects: 2569
Study 27208972 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) treatment
Number of subjects: 14
Study 27208972 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 14
Study 25294957 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training program (6 weeks)
Number of subjects: 20
Study 25294957 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 20
Study 22767583 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy extended-field radiotherapy (EF-RT)
Number of subjects: 1204
Study 22767583 — intervention group
Group type: COMPARATOR
Intervention: 30 Gy involved-field radiotherapy (IF-RT)
Number of subjects: 1204
Study 20589459 — intervention group
Group type: EXPERIMENTAL
Intervention: Poractant (curosurf)
Number of subjects: 150
Study 20589459 — intervention group
Group type: COMPARATOR
Intervention: Beractant (Survanta)
Number of subjects: 150
Study 17493477 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 1024
Study 16125491 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-beta-estradiol eluting stent
Number of subjects: 0
Study 16125491 — intervention group
Group type: COMPARATOR
Intervention: Phosphorylcholine-coated stent
Number of subjects: 0
Study 11959616 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice with praziquantel
Number of subjects: 0
Study 11959616 — intervention group
Group type: COMPARATOR
Intervention: Water treatment with praziquantel
Number of subjects: 0
Study 10096460 — intervention group
Group type: COMPARATOR
Intervention: naproxen
Number of subjects: 0
Study 10096460 — intervention group
Group type: COMPARATOR
Intervention: dydrogesterone
Number of subjects: 0
Study 10096460 — intervention group
Group type: COMPARATOR
Intervention: danazol
Number of subjects: 0
Study 10096460 — intervention group
Group type: COMPARATOR
Intervention: leuprolide
Number of subjects: 0
Study 10096460 — intervention group
Group type: EXPERIMENTAL
Intervention: laser laparoscopy
Number of subjects: 0
Study 10096460 — intervention group
Group type: EXPERIMENTAL
Intervention: oral contraceptives
Number of subjects: 0
Study 10096460 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex
Number of subjects: 0
Study 10096460 — intervention group
Group type: EXPERIMENTAL
Intervention: gestrinone
Number of subjects: 0
Study 10096460 — intervention group
Group type: EXPERIMENTAL
Intervention: nafarelin
Number of subjects: 0
Study 7503194 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline (n = 50)
Number of subjects: 184
Study 7503194 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline (n = 41)
Number of subjects: 184
Study 7503194 — intervention group
Group type: COMPARATOR
Intervention: Control (no oral terbutaline, n = 53)
Number of subjects: 184
Study 7503194 — intervention group
Group type: COMPARATOR
Intervention: Control (no oral terbutaline, n = 40)
Number of subjects: 184
Study 7503194 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline
Number of subjects: 184
Study 7503194 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 184
Study 2188763 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg APD intravenously
Number of subjects: 10
Study 2188763 — intervention group
Group type: COMPARATOR
Intervention: Control saline infusion
Number of subjects: 10
Study 6999345 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate
Number of subjects: 3892
Study 6999345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3892
Study 6999345 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate (Good Adherers)
Number of subjects: 3892
Study 6999345 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate (Poor Adherers)
Number of subjects: 3892
Study 6999345 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Good Adherers)
Number of subjects: 3892
Study 6999345 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Poor Adherers)
Number of subjects: 3892
Study 30758294 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-use group (iApp)
Number of subjects: 97
Study 30758294 — intervention group
Group type: COMPARATOR
Intervention: Delayed use group (dApp)
Number of subjects: 97
Study 29038221 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0
Study 29038221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25563826 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (0.2 mg/kg/h, up to 0.8 mg/kg/h)
Number of subjects: 74
Study 25563826 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacrynic Acid (0.2 mg/kg/h, up to 0.8 mg/kg/h)
Number of subjects: 74
Study 25563826 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 74
Study 25563826 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacrynic Acid
Number of subjects: 74
Study 23975856 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) shrinkage treatment
Number of subjects: 38
Study 23975856 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical treatment (Control)
Number of subjects: 38
Study 21120480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib administered in fed state
Number of subjects: 60
Study 21120480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib 30 mg/day (fixed-dose)
Number of subjects: 60
Study 21120480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib (general)
Number of subjects: 60
Study 21120480 — intervention group
Group type: COMPARATOR
Intervention: Cediranib administered in fasted state
Number of subjects: 60
Study 19434533 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intraperitoneal chemotherapy combined with systemic chemotherapy
Number of subjects: 332
Study 19434533 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy alone
Number of subjects: 332
Study 19434533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy regimen with Oxaliplatin
Number of subjects: 332
Study 19434533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy regimen with Cisplatin
Number of subjects: 332
Study 16752583 — intervention group
Group type: EXPERIMENTAL
Intervention: BD(DXA)
Number of subjects: 17
Study 16752583 — intervention group
Group type: EXPERIMENTAL
Intervention: BD(MD)
Number of subjects: 17
Study 16752583 — intervention group
Group type: EXPERIMENTAL
Intervention: BD(DXA) and BD(MD)
Number of subjects: 17
Study 16752583 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical DXA densitometers
Number of subjects: 17
Study 12634436 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCTs)
Number of subjects: 24
Study 12634436 — intervention group
Group type: COMPARATOR
Intervention: Long-chain triglycerides (LCTs)
Number of subjects: 24
Study 10692004 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated fish oil (FO) providing 2.1 g eicosapentaenoic acid (EPA) plus 1.1 g docosahexaenoic acid (DHA) per day for 12 weeks
Number of subjects: 0
Study 10692004 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil (3:1 mix of coconut and soybean oils)
Number of subjects: 0
Study 10692004 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (OO)
Number of subjects: 0
Study 10692004 — intervention group
Group type: COMPARATOR
Intervention: Safflower oil (SO)
Number of subjects: 0
Study 10692004 — intervention group
Group type: COMPARATOR
Intervention: Evening primrose oil (EPO)
Number of subjects: 0
Study 9109791 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionation radiotherapy
Number of subjects: 336
Study 9109791 — intervention group
Group type: COMPARATOR
Intervention: Hyperfractionation radiotherapy
Number of subjects: 336
Study 9109791 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery after radiotherapy
Number of subjects: 336
Study 8259343 — intervention group
Group type: EXPERIMENTAL
Intervention: buserelin+nilutamide (Anandron)
Number of subjects: 36
Study 8259343 — intervention group
Group type: COMPARATOR
Intervention: buserelin+placebo
Number of subjects: 36
Study 3896665 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg dimetophrine
Number of subjects: 30
Study 3896665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30466512 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP-guided therapy
Number of subjects: 894
Study 30466512 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 894
Study 26899862 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone (8 mg mixed with ropivacaine)
Number of subjects: 120
Study 26899862 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (8 mg)
Number of subjects: 120
Study 26899862 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 120
Study 26899862 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone
Number of subjects: 120
Study 26899862 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 120
Study 26899862 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (both routes)
Number of subjects: 120
Study 25514302 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (0.5 mg daily)
Number of subjects: 121
Study 25514302 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (100 mg daily)
Number of subjects: 121
Study 22537778 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (α-Vit E)
Number of subjects: 7
Study 22537778 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (Vit C)
Number of subjects: 7
Study 22537778 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol acetate (α-Vit E-acetate)
Number of subjects: 7
Study 22537778 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoic acid
Number of subjects: 7
Study 22537778 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbyl 6-palmitate
Number of subjects: 7
Study 22537778 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid 2-glucoside
Number of subjects: 7
Study 22537778 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione (GSH)
Number of subjects: 7
Study 20575613 — intervention group
Group type: EXPERIMENTAL
Intervention: e-contact via e-mail and SMS communication
Number of subjects: 49
Study 20575613 — intervention group
Group type: EXPERIMENTAL
Intervention: e-contact via SMS
Number of subjects: 49
Study 20575613 — intervention group
Group type: EXPERIMENTAL
Intervention: e-contact via e-mail
Number of subjects: 49
Study 17638396 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (16.6mg nicotine/patch) in former smokers (group 2)
Number of subjects: 75
Study 17638396 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-smokers, group 1)
Number of subjects: 75
Study 17638396 — intervention group
Group type: COMPARATOR
Intervention: Control group (current smokers, group 3)
Number of subjects: 75
Study 16054963 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive patch (n = 846)
Number of subjects: 1489
Study 16054963 — intervention group
Group type: COMPARATOR
Intervention: Oral contraception (OC) (n = 643)
Number of subjects: 1489
Study 16054963 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive patch
Number of subjects: 1489
Study 12134249 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal interferon (IFN)‐alpha2b (6 x 10(6) U every 12 h x 3) plus oral chlorpheniramine (12 mg extended release) and ibuprofen (400 mg) every 12 h for 4.5 days (n=59 subjects)
Number of subjects: 150
Study 12134249 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo plus oral chlorpheniramine and ibuprofen (n=61 subjects)
Number of subjects: 150
Study 12134249 — intervention group
Group type: COMPARATOR
Intervention: Intranasal and oral placebos (n=30 subjects)
Number of subjects: 150
Study 11756911 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of music and patient-controlled sedation with a mixture of propofol and alfentanil
Number of subjects: 165
Study 11756911 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled sedation alone
Number of subjects: 165
Study 11756911 — intervention group
Group type: COMPARATOR
Intervention: Music alone with diazemuls and meperidine administered intravenously if requested
Number of subjects: 165
Study 11756911 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of music and patient-controlled sedation
Number of subjects: 165
Study 9744709 — intervention group
Group type: EXPERIMENTAL
Intervention: Interregional nurse-coordinated cardiovascular health care model
Number of subjects: 154
Study 9744709 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (standard care)
Number of subjects: 154
Study 7838930 — intervention group
Group type: EXPERIMENTAL
Intervention: Low nicotine cigarette condition
Number of subjects: 29
Study 7838930 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium nicotine cigarette condition
Number of subjects: 29
Study 7838930 — intervention group
Group type: EXPERIMENTAL
Intervention: High nicotine cigarette condition
Number of subjects: 29
Study 7838930 — intervention group
Group type: COMPARATOR
Intervention: Sham smoking condition
Number of subjects: 29
Study 7838930 — intervention group
Group type: COMPARATOR
Intervention: Non-smoking condition
Number of subjects: 29
Study 2904237 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily treatment with streptomycin, isoniazid, rifampin, and pyrazinamide for 2 months (2SHRZ) followed by 3‐times‐weekly isoniazid and rifampin (H3 R3)
Number of subjects: 297
Study 2904237 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily treatment with isoniazid, rifampin, and pyrazinamide for 1 month (1SHRZ) followed by 3‐times‐weekly isoniazid and rifampin (H3 R3)
Number of subjects: 297
Study 2904237 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily treatment with isoniazid, rifampin, and pyrazinamide for 2 months without streptomycin (2HRZ) followed by 3‐times‐weekly isoniazid and rifampin (H3 R3)
Number of subjects: 297
Study 2904237 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with drug‐susceptible strains pretreatment
Number of subjects: 297
Study 2904237 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with strains resistant to isoniazid, streptomycin, or both drugs pretreatment
Number of subjects: 297
Study 29189607 — intervention group
Group type: EXPERIMENTAL
Intervention: K12 (2.5 × 10(9) cfu per lozenge)
Number of subjects: 1314
Study 29189607 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 1314
Study 29189607 — intervention group
Group type: EXPERIMENTAL
Intervention: K12
Number of subjects: 1314
Study 27543900 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary delivery of allogeneic cardiosphere-derived cells (CAP-1002)
Number of subjects: 120
Study 27543900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 26852498 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intermittent pneumatic compression, kinesio-taping, and underwater massage shower
Number of subjects: 30
Study 26852498 — intervention group
Group type: COMPARATOR
Intervention: Intermittent pneumatic compression and underwater massage shower
Number of subjects: 30
Study 23287525 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 ms ultra-brief pulse right unilateral ECT
Number of subjects: 35
Study 23287525 — intervention group
Group type: COMPARATOR
Intervention: 1 ms-brief pulse right unilateral ECT
Number of subjects: 35
Study 21636200 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper threshold normocapnia (corrected pCO₂ 6.0 kPa)
Number of subjects: 8
Study 21636200 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower threshold normocapnia (non-corrected pCO₂ 4.2 kPa)
Number of subjects: 8
Study 18055869 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine and cyclophosphamide (FC)
Number of subjects: 777
Study 18055869 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine (single-agent)
Number of subjects: 777
Study 18055869 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil or Fludarabine
Number of subjects: 777
Study 18055869 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine monotherapy
Number of subjects: 777
Study 18055869 — intervention group
Group type: EXPERIMENTAL
Intervention: DAT status at initiation of therapy
Number of subjects: 777
Study 16476713 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (CBX) 200 mg/24 h
Number of subjects: 30
Study 16476713 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac (ACF) 100 mg/12 h
Number of subjects: 30
Study 16476713 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with OA who did not want to be treated with NSAIDs)
Number of subjects: 30
Study 12730296 — intervention group
Group type: COMPARATOR
Intervention: Nonfat placebo beverage (NF)
Number of subjects: 15
Study 12730296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfat beverage with added phytosterols (NFPS)
Number of subjects: 15
Study 12730296 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat beverage with added phytosterols (LFPS)
Number of subjects: 15
Study 11099750 — intervention group
Group type: EXPERIMENTAL
Intervention: INN 00835 (0.2 mg/kg subcutaneously for 5 consecutive days)
Number of subjects: 52
Study 11099750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 11099750 — intervention group
Group type: EXPERIMENTAL
Intervention: INN 00835
Number of subjects: 52
Study 9368550 — intervention group
Group type: EXPERIMENTAL
Intervention: t-PA treatment
Number of subjects: 312
Study 1311535 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of mivacurium at a rate of 6 +/- 2 micrograms.kg‐1.min‐1 after an initial bolus of 2 x ED95.
Number of subjects: 65
Study 1311535 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated injection of mivacurium at 0.6 x ED95 whenever twitch tension recovered to 25% of control.
Number of subjects: 65
Study 1311535 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine (7 micrograms/kg) administered at 25% twitch recovery in both groups.
Number of subjects: 65
Study 30777901 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 120
Study 30777901 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (MDZ)
Number of subjects: 120
Study 28285208 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline and cognitive-behavioral therapy for smoking cessation
Number of subjects: 153
Study 26211378 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 60
Study 26211378 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 60
Study 23541425 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1386
Number of subjects: 103
Study 23541425 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 103
Study 23541425 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 103
Study 21129711 — intervention group
Group type: EXPERIMENTAL
Intervention: Right radial approach
Number of subjects: 193
Study 21129711 — intervention group
Group type: COMPARATOR
Intervention: Left radial approach
Number of subjects: 193
Study 19387697 — intervention group
Group type: EXPERIMENTAL
Intervention: Wallis interspinous implant (group W)
Number of subjects: 45
Study 19387697 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 45
Study 16452735 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (30 mg, administered subcutaneously twice a day) starting 24-48 hours after blunt trauma
Number of subjects: 200
Study 16452735 — intervention group
Group type: COMPARATOR
Intervention: Pulsatile foot pumps at admission combined with delayed enoxaparin
Number of subjects: 200
Study 14747633 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine, Paroxetine, or Sertraline (SSRI antidepressants)
Number of subjects: 573
Study 11734484 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-strand gracilis and semitendinosus tendon autograft (hamstring tendon group)
Number of subjects: 72
Study 11734484 — intervention group
Group type: COMPARATOR
Intervention: Patellar tendon-bone autograft (patellar tendon group)
Number of subjects: 72
Study 9159623 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic homograft (group A)
Number of subjects: 70
Study 9159623 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary autograft (group B)
Number of subjects: 70
Study 7659908 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole Tc99m sestaMIBI SPECT
Number of subjects: 37
Study 7659908 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone-echocardiography
Number of subjects: 37
Study 2441458 — intervention group
Group type: EXPERIMENTAL
Intervention: Elmiron 200 mg X 2 daily
Number of subjects: 24
Study 2441458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29580885 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention consisting of educational lectures, posters, and pocket cards for thromboprophylaxis guidelines.
Number of subjects: 2962
Study 29580885 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention in post-acute care wards.
Number of subjects: 2962
Study 29580885 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention in long-term care wards.
Number of subjects: 2962
Study 29580885 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 2962
Study 26964857 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional complete denture group
Number of subjects: 20
Study 26964857 — intervention group
Group type: COMPARATOR
Intervention: Duplicate complete denture group
Number of subjects: 20